Clinical Indices for Pediatric Inflammatory Bowel Disease Research

  • Angela Noble
  • Dan Turner


Inflammatory Bowel Disease Ulcerative Colitis Crohn Disease Clinical Index Height Velocity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kirshner B, Guyatt G. A methodological framework for assessing health indices. J Chronic Dis 1985;38:27–36.PubMedCrossRefGoogle Scholar
  2. 2.
    Wright JG, Feinstein AR. A comparative contrast of clinimetric and psychometric methods for constructing indexes and rating scales. J Clin Epidemiol 1992;45:1201–18.PubMedCrossRefGoogle Scholar
  3. 3.
    Marx RG, Bombardier C, Hogg-Johnson S, Wright JG. Clinimetric and psychometric strategies for development of a health measurement scale. J Clin Epidemiol 1999;52:105–11.PubMedCrossRefGoogle Scholar
  4. 4.
    Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002;11:193–205.Google Scholar
  5. 5.
    Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, McDonald JW. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian CrohnRelapse Prevention Trial Study Group. Gastroenterology 1994;106: 287–96.PubMedGoogle Scholar
  6. 6.
    Yoshida EM. The Crohn disease Activity Index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn disease. Can J Gastroenterol 1999;13:65–73.PubMedGoogle Scholar
  7. 7.
    Streiner DLN, Geoffrey R. Health measurement scales a practical guide to their development and use. Oxford University Press, 1995.Google Scholar
  8. 8.
    Portney LG, Watkins MP. Foundations of clinical research applications to practice. 2nd ed. Upper Saddle River: Prentice Hall, 2000:557–86.Google Scholar
  9. 9.
    Liang MH. Evaluating measurement responsiveness. J Rheumatol 1995;22:1191–2.PubMedGoogle Scholar
  10. 10.
    Deyo RA, Centor RM. Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chronic Dis 1986;39:897–906.PubMedCrossRefGoogle Scholar
  11. 11.
    Beaton DE. Understanding the relevance of measured change through studies of responsiveness. Spine 2000;25:3192–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Beaton DE, Bombardier C, Katz JN, Wright JG. A taxonomy for responsiveness. J Clin Epidemiol 2001;54:1204–17.PubMedCrossRefGoogle Scholar
  13. 13.
    Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn disease activity index. National Cooperative Crohn disease Study. Gastroenterology 1976;70:439–44.PubMedGoogle Scholar
  14. 14.
    de Dombal FT, Softley A. IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut 1987;28:474–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Sands BE, Ooi CJ. A survey of methodological variation in the Crohn disease activity index. Inflamm Bowel Dis 2005;11:133–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980;1:514.PubMedCrossRefGoogle Scholar
  17. 17.
    Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn disease. Gastroenterology 2000;119:895–902.PubMedCrossRefGoogle Scholar
  18. 18.
    Escher JC. Budesonide versus prednisolone for the treatment of active Crohn disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004;16:47–54.PubMedCrossRefGoogle Scholar
  19. 19.
    Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, Griffiths AM, Katz AJ, Grand RJ, Boyle JT, et al. Development and validation of a pediatric Crohn disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439–47.PubMedGoogle Scholar
  20. 20.
    Otley A, Loonen H, Parekh N, Corey M, Sherman PM, Griffiths AM. Assessing activity of pediatric Crohn disease: which index to use? Gastroenterology 1999;116:527–31.PubMedCrossRefGoogle Scholar
  21. 21.
    Kundhal PS, Critch JN, Zachos M, Otley AR, Stephens D, Griffiths AM. Pediatric Crohn Disease Activity Index: responsive to short-term change. J Pediatr Gastroenterol Nutr 2003;36:83–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, Kugathasan S, Pfefferkorn M, Tolia V, Evans J, Treem W, Wyllie R, Rothbaum R, del Rosario J, Katz A, Mezoff A, Oliva-Hemker M, Lerer T, Griffiths A. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005;41:416–21.PubMedCrossRefGoogle Scholar
  23. 23.
    Loonen HJ, Griffiths AM, Merkus MP, Derkx HH. A critical assessment of items on the Pediatric Crohn disease Activity Index. J Pediatr Gastroenterol Nutr 2003;36:90–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Shepanski MA, Markowitz JE, Mamula P, Hurd LB, Baldassano RN. Is an abbreviated Pediatric Crohn disease activity index better than the original? J Pediatr Gastroenterol Nutr 2004;39:68–72.PubMedCrossRefGoogle Scholar
  25. 25.
    Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985;107:317–29.PubMedCrossRefGoogle Scholar
  26. 26.
    Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II. Arch Dis Child 1966;41:613–35.PubMedGoogle Scholar
  27. 27.
    Schwartz DA, Loftus EV, Jr., Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn disease. Gut 1980;21:525–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Irvine EJ. Usual therapy improves perianal Crohn disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27–32.PubMedCrossRefGoogle Scholar
  30. 30.
    Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn disease. N Engl J Med 1999;340:1398–405.PubMedCrossRefGoogle Scholar
  31. 31.
    Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn disease. Aliment Pharmacol Ther 2003;18:1113–20.PubMedCrossRefGoogle Scholar
  32. 32.
    West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, Kuipers EJ. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004;20:1329–36.PubMedCrossRefGoogle Scholar
  33. 33.
    Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn disease: the CHARM trial. Gastroenterology 2007;132:52–65.PubMedCrossRefGoogle Scholar
  34. 34.
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041–8.PubMedGoogle Scholar
  35. 35.
    Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978;13:833–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894–8.PubMedGoogle Scholar
  37. 37.
    Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Bmj 1989;298:82–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990;336:16–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992;87:971–6.PubMedGoogle Scholar
  40. 40.
    Seo M, Okada M, Yao T, Okabe N, Maeda K, Oh K. Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts’ classification. Am J Gastroenterol 1995;90:1759–63.PubMedGoogle Scholar
  41. 41.
    Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998;43:29–32.PubMedCrossRefGoogle Scholar
  42. 42.
    Azzolini F, Pagnini C, Camellini L, Scarcelli A, Merighi A, Primerano AM, Bertani A, Antonioli A, Manenti F, Rigo GP. Proposal of a new clinical index predictive of endoscopic severity in ulcerative colitis. Dig Dis Sci 2005;50:246–51.PubMedCrossRefGoogle Scholar
  43. 43.
    Beattie RM, Nicholls SW, Domizio P, Williams CB, Walker-Smith JA. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 1996;22:373–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Irvine E. Assessing outcomes in clinical trials. In: Satsangi J, ed. Inflammatory bowel disease. Philadelphia: Churchill Livingstone, 2003:319–33.Google Scholar
  45. 45.
    D’Haens GS, WJ; Feagan, BG, Geboes, K, Hanauer, SB, Irvine, EJ, Lemann, M, Marteau, P, Rutgeerts, P, Scholmerich, J, Sutherland, LR. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763–86.CrossRefGoogle Scholar
  46. 46.
    Lloyd-Still JD, Green OC. A clinical scoring system for chronic inflammatory bowel disease in children. Dig Dis Sci 1979;24:620–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Beattie RM, Nicholls SW, Domizio P, Williams CB, Walker-Smith JA. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 1996;22:373–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Turner D, Otley A, deBruijne J, Mack, D, Uusoue, K, Zachos, M, Mamula, P, Hyams, J, Griffiths, A.M. Development of a pediatric ulcerative colitis activity index (PUCAI). J Pediatr Gastroenterol Nutr 2006;43:E47.Google Scholar
  49. 49.
    Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, D’Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ. European evidence based consensus on the diagnosis and management of Crohn disease: current management. Gut 2006;55 Suppl 1:i16–35.PubMedCrossRefGoogle Scholar
  50. 50.
    Reproducibility of colonoscopic findings in Crohn disease: a prospective multicenter study of interobserver variation. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Dig Dis Sci 1987;32:1370–9.Google Scholar
  51. 51.
    Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn disease. Gastrointest Endosc 2006;63:433–42; quiz 464.PubMedCrossRefGoogle Scholar
  53. 53.
    D’Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn disease: A European multicenter trial. Gastroenterology 1999;116:1029–34.PubMedCrossRefGoogle Scholar
  54. 54.
    Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn disease. Gut 1997;40:470–4.PubMedGoogle Scholar
  55. 55.
    Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P. Development and validation of a new, simplified endoscopic activity score for Crohn disease: The SES-CD. Gastrointest Endosc 2004;60:505–12.PubMedCrossRefGoogle Scholar
  56. 56.
    Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665–72.PubMedCrossRefGoogle Scholar
  57. 57.
    Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn disease. Gastroenterology 1990;99:956–63.PubMedGoogle Scholar
  58. 58.
    Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F, Noman M, Aerden I, De Hertogh G, Geboes K, Hiele M, D’Hoore A, Penninckx F. Ornidazole for prophylaxis of postoperative Crohn disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128: 856–61.Google Scholar
  59. 59.
    Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004;127:723–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964;1:89–92.PubMedGoogle Scholar
  61. 61.
    Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993;88:1188–97.PubMedGoogle Scholar
  62. 62.
    Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.PubMedCrossRefGoogle Scholar
  63. 63.
    Orlandi F, Brunelli E, Feliciangeli G, Svegliati-Baroni G, Di Sario A, Benedetti A, Guidarelli C, Macarri G. Observer agreement in endoscopic assessment of ulcerative colitis. Ital J Gastroenterol Hepatol 1998;30:539–41.PubMedGoogle Scholar
  64. 64.
    Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD, Sandborn WJ, Steinhart AH. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis 2005;11 Suppl 1:S22–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Mackner LM, Crandall WV, Szigethy EM. Psychosocial functioning in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2006;12:239–44.PubMedCrossRefGoogle Scholar
  66. 66.
    Sainsbury A, Heatley RV. Review article: Psychosocial factors in the quality of life of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005;21:499–508.PubMedCrossRefGoogle Scholar
  67. 67.
    Sandler RS, Jordan MC, Kupper LL. Development of a Crohnindex for survey research. J Clin Epidemiol 1988;41:451–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Griffiths AM, Otley AR, Hyams J, Quiros AR, Grand RJ, Bousvaros A, Feagan BG, Ferry GR. A review of activity indices and end points for clinical trials in children with Crohn disease. Inflamm Bowel Dis 2005;11:185–96.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Angela Noble
    • 1
  • Dan Turner
  1. 1.Clinical Instructor in Pediatrics, Department of Gastroenterology, Hepatology and NutritionSt. Justine Hospital, University of MontrealMontrealCanada

Personalised recommendations